4
Changes in Ownership
SAB Biotherapeutics, Inc. Filed Acc 0001493152-21-026390
Chief Business Officer acquired 38,596 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Finnegan Frederick Chief Business Officer | 2021-10-22 | Grant or award | +38,596 | 38,596 | D: show line 1 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Finnegan Frederick Chief Business Officer | 2021-10-22 | Grant or award · Earnout Rights (Common Stock) | +15,593 | 15,593 | D: show line 2 in the form | |||||
| Finnegan Frederick Chief Business Officer | 2021-10-22 | Grant or award · Employee Stock Option (right to buy) | +23,264 | 23,264 | D: show line 3 in the form | |||||
| Finnegan Frederick Chief Business Officer | 2021-10-22 | Grant or award · Employee Stock Option (right to buy) | +125,627 | 125,627 | D: show line 4 in the form | |||||
| Finnegan Frederick Chief Business Officer | 2021-10-22 | Grant or award · Earnout Rights (Restricted Stock Units) | +60,152 | 60,152 | D: show line 5 in the form |
Loading xslF345X03/ownership.xml…